Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2023-12-01
- Target Recruit Count
- 12
- Registration Number
- NCT03864406
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Rivaroxaban Hypericum Trial
- Conditions
- Interventions
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 12
- Registration Number
- NCT03796377
- Locations
- 🇨🇭
Inselspital, Bern, Switzerland
A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2019-03-19
- Target Recruit Count
- 80
- Registration Number
- NCT03792152
Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
- Conditions
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03786757
- Locations
- 🇨🇳
Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-04-18
- Target Recruit Count
- 400
- Registration Number
- NCT03772457
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT03764241
- Locations
- 🇨🇳
Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Target Recruit Count
- 400
- Registration Number
- NCT03749057
- Locations
- 🇨🇳
General Hospital of ShenYang Military Region, Shenyang, China
Efficacy Comparison of Warfarin Versus Rivaroxaban CVT
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT03747081
- Locations
- 🇮🇷
Alzahra University Hospital, Isfahan, Iran, Islamic Republic of
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03702582
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University College, London
- Target Recruit Count
- 43
- Registration Number
- NCT03684564
- Locations
- 🇬🇧
Barts and the London Hospitals, Barts Health NHS Trust, London, United Kingdom
🇬🇧Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧University College Hospitals NHS Foundation Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.